期刊
AMERICAN JOURNAL OF SURGERY
卷 197, 期 3, 页码 313-318出版社
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjsurg.2008.10.007
关键词
Carcinoid tumor; Extracellular-regulated kinase pathway; Ref 1; Targeted therapies; Tautomycin
类别
资金
- NCI NIH HHS [CA113297, R01 CA109053-02, R21 CA117117, R01 CA109053-01A2, R21 CA117117-02, CA109053, R01 CA109053, R01 CA109053-03, R21 CA117117-01A2] Funding Source: Medline
- NIDDK NIH HHS [R21 DK064735, DK064735, DK066169, R21 DK066169] Funding Source: Medline
BACKGROUND: Carcinoids are neuroendocrine (NE) tumors with limited treatment options. Raf-1 pathway activation has been shown to suppress hormone production in carcinoid cells. We investigated a novel treatment for carcinoid cell growth based on pharmacologic Raf-1 activation using the compound tautomycin (TTY). METHODS: Human carcinoid cells were treated with TTY for 48 hours. Western blot analysis was used to demonstrate Raf-1 pathway activation by phosphorylation of ERK1/2 and to determine the effect on NE tumor markers. Cellular growth was measured by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay. RESULTS: Treatment with TTY resulted in dose-dependent activation of the Raf-1 pathway. Furthermore, a significant decrease in NE tumor markers was seen. Importantly, TTY inhibited carcinoid cellular growth and induced the cell-cycle inhibitors p21 and p27. CONCLUSION: TTY activates the Raf-1 pathway, limits carcinoid cell growth, and suppresses NE market production in vitro. This new Compound warrants further investigation in animal models of carcinoid cancer. (C) 2009 Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据